Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  For the Patient  |  Careers at Hemispherx  


Officers and Directors
Officers and Directors Bios
Scientific Advisory Board
Hemispherx Biopharma Locations
Key Contacts
Corporate Alliances

 

Officers & Directors Bios

William A. Carter, M.D.
Chairman of the Board, Chief Executive Officer

Dr. Carter, the co-inventor of Ampligen®, joined the Company in 1978, and has served as the Company's Chief Scientific Officer since May 1989, the Chairman of the Company's Board of Directors since January 1992, the Company's Chief Executive Officer since July 1993, the Company's President since April, 1995, and a director since 1987. From 1987 to 1988, Dr. Carter served as the Company's Chairman. Dr. Carter was a leading innovator in the development of human interferon for a variety of treatment indications including various viral diseases and cancer. In this context, he received the first FDA approval to initiate clinical trials on a beta interferon product manufactured in the U.S. under his supervision. From 1985 to October 1988, Dr. Carter served as the Company's Chief Executive Officer and Chief Scientist. He received his M.D. degree from Duke University and underwent his post-doctoral training at the National Institutes of Health and Johns Hopkins University. Dr. Carter also served as Professor of Neoplastic Diseases at Hahneman Medical University, a position he held from 1980 to 1998. He also served as Director of Clinical Research for Hahneman Medical University's Institute for Cancer and Blood Diseases, and as a professor at Johns Hopkins School of Medicine and the State University of New York at Buffalo. He is a Board certified physician and author of more than 200 scientific articles, including the editing of various textbooks on anti-viral and immune therapy.
Back

 
Charles T. Bernhardt
Chief Financial Officer
 

Mr. Bernhardt has served as Chief Financial Officer of the Company since January 2009.  Prior to joining Hemispherx, Mr. Bernhardt most recently was the Director of Accounting for Healthcare Division of Thomson Reuters (NYSE-TRI), an overall company with $12 billion in annual revenues and 50,000 total world-wide employees. He was responsible for their Healthcare Division’s accounting operations as well as the shared financial services for the Healthcare and Scientific Divisions. Earlier in his career, he was a Regional Controller for Comcast Cable, Director of Finance for TelAmerica Media and is an alumni of public accounting’s Big Four in KPMG.  Mr. Bernhardt is a graduate of Villanova University with a Bachelor of Science in Accountancy and an MBA from West Chester University. 
Back
 
David R. Strayer, M.D. 
Medical Director - Regulatory Affairs
 

Dr. Strayer, who served as Professor of Medicine at the Medical College of Pennsylvania and Hahnemann University, has acted as the Medical Director of the Company since 1986. He is Board Certified in Medical Oncology and Internal Medicine with research interests in the fields of cancer and immune system disorders. Dr. Strayer has served as principal investigator in studies funded by the Leukemia Society of America, the American Cancer Society, and the National Institutes of Health. Dr. Strayer attended the School of Medicine at the University of California at Los Angeles where he received his M.D. in 1972. 
Back

 
 
Thomas K. Equels Thomas K. Equels 
Director
 

TOM EQUELS was appointed to the Board of Directors on November 11, 2008.  Mr. Equals is the President and Managing Director of the Equels Law Firm. His practice is devoted to complex litigation, with particular emphasis on civil racketeering, business torts and commercial matters. For more than 25 years Tom has represented national and state governments, and companies in the banking, insurance, aviation, pharmaceutical, construction and development industries. He has extensive experience in international matters and has served as counsel for the Republic of Panama and Chinese National Petroleum Corp. He has worked extensively in Europe, as well as in South America, Asia and Africa. Mr. Equels received his law degree with high honors from Florida State University and is a graduate Summa Cum Laude of Troy State University.
Back

 

Iraj E. Kiani, N.D., Ph.D.
Director
 

IRAJ E. KIANI, M.B.A., Ph.D., was appointed to the Board of Directors on May 1, 2002. Dr. Kiani is a citizen of England and resides in Newport, California. Dr. Kiani served in various local government position including the Governor of Yasoi, Capital of Boyerahmand, Iran. In 1980, Dr. Kiani moved to England, where he established and managed several trading companies over a period of some 20 years. Dr. Kiani is a planning and logistic specialist who is now applying his knowledge and experience to build a worldwide immunology network, which will use the Company's proprietary technology. Dr. Kiani received his Ph.D. degree from the University of Ferdosi in Iran.
Back
 
William M. Mitchell, M.D. 
Director 

William M. Mitchell, M.D. has been a director of ours since July 1998. Dr. Mitchell is a Professor of Pathology at Vanderbilt University School of Medicine. Dr. Mitchell earned a M.D. from Vanderbilt and a Ph.D. from Johns Hopkins University, where he served as an Intern in Internal Medicine, followed by a Fellowship at its School of Medicine. Dr. Mitchell has published over 200 papers, reviews and abstracts dealing with viruses and anti-viral drugs. Dr. Mitchell has worked for and with many professional societies, including the International Society for Interferon Research, and committees, among them the National Institutes of Health, AIDS and Related Research Review Group. Dr. Mitchell previously served as a director of Hemispherx from 1987 to 1989. 
Back
 
Richard C. Piani
Director

Mr. Piani has served as a Director of the Company since May 1995. Mr. Piani has been employed as a principal delegate for Industry to the City of Science and Industry, Paris, France, a billion dollar scientific and educational complex since 1995. Mr. Piani provided consulting to the Company in 1993, with respect to general business strategies for the Company's European operations and markets. He served as Chairman of Industrielle du Batiment-Morin, a building materials corporation, from 1986 to 1993. Previously he was Professor of International Strategy at Paris Dauphine University from 1984 to 1993. From 1979 to 1985 Mr. Piani served as Group Director in Charge of International and Commercial Affairs for Rhone-Poulenc and from 1973 to 1979 was Chairman and Chief Executive Officer of Societe "La Cellophane", the French company which invented cellophane and several other worldwide products. Mr. Piani has a Law degree from Facilite de Droit, Paris Sorbonne and a Business Administration degree from Ecola des Hautes Etudes Commerciales, Paris. 
Back
 

 

 
Information contained on the Hemispherx website other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed on the Hemispherx website and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgement as of the date of this website. The Company disclaims, however, any intent or obligation to update these forward-looking statements.